Drugs / Vepugratinib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06644378 | Oct 2024 → Jan 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06641037 | Oct → Dec 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05614739 | Jan 2023 → Jun 2027 expected | metastatic neoplasm, ureter neoplasm, urinary bladder neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07218380 | Dec 2025 → Oct 2029 expected | metastatic malignant neoplasm, transitional cell carcinoma, urinary bladder cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07675057 | — | metastatic neoplasm, transitional cell carcinoma, urinary bladder neoplasm | Eli Lilly and Company | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vepugratinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07675057 ↗ |
| Known as | LOXO-435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05614739 ↗ |
| Known as | LY3866288 | “FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3” NCT05614739 ↗3“A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract” NCT07218380 ↗ |
| Route | Oral | “LOXO-435 administered orally” NCT05614739 ↗ |